China Shineway Pharmaceutical : Announcements and Notices - Turnover for the First Quarter of 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 02877)

TURNOVER FOR THE FIRST QUARTER OF 2019

The board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company") is pleased to announce that, the turnover of the Company and its subsidiaries (together, the "Group") for the three months ended 31 March 2019 ("the First Quarter of 2019") based on its management accounts which have not been reviewed by the auditors, reached RMB636,000,000, representing a decrease of 5.1% as compared with the same quarter of 2018, and in particular:

-Turnover of injection products decreased by 21.4% to RMB290,000,000;

-Turnover of soft capsule products increased by 12.2% to RMB110,000,000;

-Turnover of granule products decreased by 27.4% to RMB85,000,000;

-Turnover of TCM formula granule products increased by 116.7% to RMB117,000,000; and

-Turnover of products in other forms increased by 6.3% to RMB34,000,000.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 45.6%, 17.3%, 13.4% and 18.4% of the total turnover respectively for the First Quarter of 2019.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board

China Shineway Pharmaceutical Group Limited

Li Zhenjiang

Chairman

Hong Kong, 3 May 2019

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin, Mr. Chen Zhong and Mr. Xu Sheng,; and the independent non-executiveDirectors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Cheung Chun Yue Anthony.